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Bromodomain Inhibitors as
Therapeutics for
Herpesvirus-Related Disease: All
BETs Are Off?
Ian J. Groves*†, John H. Sinclair † and Mark R. Wills †
Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
Although the ubiquitous human herpesviruses (HHVs) are rarely associated with serious
disease of the healthy host, primary infection and reactivation in immunocompromised
individuals can lead to significant morbidity and, in some cases, mortality. Effective
drugs are available for clinical treatment, however resistance is on the rise such that
new anti-viral targets, as well as novel clinical treatment strategies, are required. A
promising area of development and pre-clinical research is that of inhibitors of epigenetic
modifying proteins that control both cellular functions and the viral life cycle. Here,
we briefly outline the interaction of the host bromo- and extra-terminal domain (BET)
proteins during different stages of the HHVs’ life cycles while giving a full overview of
the published work using BET bromodomain inhibitors (BRDis) during HHV infections.
Furthermore, we provide evidence that small molecule inhibitors targeting the host
BET proteins, and BRD4 in particular, have the potential for therapeutic intervention of
HHV-associated disease.
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INTRODUCTION
The mammalian herpesviridae comprises three sub-families (alpha, beta, and gamma) that likely
arose around 200 million years ago (McGeoch et al., 1995; Mettenleiter et al., 2008). As such,
human herpesviruses (HHVs) have co-evolved with their host and primary infection is usually
associated with few minor non-life threatening symptoms, although some ailments are associated
with discomfort or more chronic manifestations (e.g., cold sores, genital lesions, mononucleosis;
summarized in Table 1) (Arvin et al., 2007). With well over 90% of the world population infected
with at least one HHV, these human pathogens have developed a particular method of maintaining
their presence in the infected host. Common to all herpesviruses, after primary infection, they
establish a so-called latent infection where virus genomes are carried in specific sites in the host
with the absence of production of infectious virions. The cellular tropism of each HHV sub-
family determines where virus lies latently for the lifetime of the host but, importantly, where it
is routinely able to undergo reactivation from, allowing the production of new infectious virions
and transmission to a new host.
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Significantly, it is reactivation of HHVs in an
immunocompromised individual that commonly leads
to life threatening illness; for instance, patients with
acquired immunodeficiency syndrome (AIDS) from human
immunodeficiency virus (HIV) infection or those undergoing
transplantation operations and who are immunosuppressed
(Arvin et al., 2007). Various anti-viral drugs can be employed
successfully both prophylactically and pre-emptively. Current
herpesvirus anti-virals used within the clinic are able to
impair DNA/RNA synthesis [e.g., (val)acyclovir, famciclovir,
(val)ganciclovir, cidofovir]. However, these nucleoside analogs
only target lytically infected cells, suffer from poor bioavailability
and can have profound toxic side effects (Field and Vere Hodge,
2013). Further compounds have been purposed experimentally
against other stages of the HHV lifecycle, including virus-
cell binding and entry, as well as virion assembly and egress
(e.g., maribavir) (Coen and Schaffer, 2003). However, even
contemporary drugs, such as letermovir that inhibits the DNA
terminase complex during human cytomegalovirus (HCMV)
replication, have rising examples of resistance (Popping et al.,
2019; Douglas et al., 2020). Therefore, with a lack of tractable
vaccinations for the majority of HHVs (with the exception
of varicella zoster virus (VZV) (Field and Vere Hodge, 2013;
Plotkin, 2020), in part due to their ability to both hide latently
and actively evade the immune system, one avenue during
iatrogenic-induced reactivation might be to reduce the latent
cell reservoir prior to clinical treatment (Krishna et al., 2019).
This is no more relevant than with HCMV reactivation during
TABLE 1 | Characteristics of human herpesvirus (HHV) infections.
HHV official
nomenclature
Common name HHV
type
Primary pathology Further clinical
conditions
Primary target
cells
Sites of
latency
Common
therapy*
HHV-1 Herpes simplex
virus 1 (HSV-1)
Alpha Cold sores Skin lesions, keratitis,
encephalitis, meningitis
Mucosal and
epithelial cells
Neurons ACV, FAM,
VAL, PCV
HHV-2 Herpes simplex
virus 2 (HSV-2)
Alpha Genital lesions, cold
sores
Skin lesions, keratitis,
encephalitis, meningitis
Mucosal and
epithelial cells
Neurons ACV, FAM,
VAL
HHV-3 Varicella zoster
virus (VZV)
Alpha Chicken pox Herpes zoster, shingles Mucosal and
epithelial cells
Neurons ACV
HHV-4 Epstein-Barr
virus (EBV)
Gamma Mononucleosis/
glandular fever
Lymphoma,
nasopharyngeal
carcinoma (NPC), T/NK
cell and gastric cancers
Epithelial and B
cells
Memory B
cells
Steroids
HHV-5 Human
cytomegalovirus
(HCMV)
Beta Mononucleosis,
mental retardation
(congenital infection)
Periodontitis, retinitis,
pneumonitis, hepatitis,
nephritis
Epithelial and
myeloid cells
Myeloid cells GCV, FOS,
LET
HHV-6A
&−6B
Roseola virus
(HHV-6)
Beta Exanthema subitum
(roseola), rash
T cells Leukocytes None
HHV-7 Roseola virus
(HHV-7)
Beta Exanthema subitum
(roseola), rash
T cells T cells None
HHV-8 Kaposi’s
sarcoma-
associated
herpesvirus
(KSHV)
Gamma Fever, rash Kaposi’s sarcoma (KS),
primary effusion
lymphoma (PEL) and
multicentric Castleman’s
Disease
Epithelial cells
and lymphocytes
B cells Radiation,
cytotoxic
drugs,
IFN-α,
GCV
*Treatments updated from Coen and Schaffer (2003). ACV, acyclovir; FAM, famciclovir; FOS, foscarnet; GCV, ganciclovir; IFN-α, interferon-α; LET, letermovir; PCV, penciclovir;
VAL, valacylovir.
solid organ or haematopoietic stem cell transplantation (SOT
or HSCT, respectively) where the prospect of a “shock and kill”
approach would be advantageous (Poole et al., 2014; Wills et al.,
2015). Here, an agent such as a small molecule inhibitor targeting
host proteins involved in the maintenance of latency allows
reactivation of the virus in a relatively healthy host such that the
immune system is able to purge the latently infected reservoir
(Nehme et al., 2019). Unfortunately, despite some success
with histone deacetylase inhibitors (HDACis), this regimen is
proving inefficient with HIV treatment (Ait-Ammar et al., 2019),
therefore further targets must be established.
Cellular transcription factors are routinely hijacked and
employed by viral pathogens throughout the course of the
viral lifecycle and one group of these is the bromo- and
extra-terminal domain (BET) proteins. The BET protein group
comprises BRD2, BRD3, BRD4, and the testis-specific BRDT
(Zaware and Zhou, 2019). In addition to an extra-terminal
domain, human BET proteins contain two BRDs (BD1 and
BD2) through which they can interact with acetylated proteins
(Filippakopoulos et al., 2012). Through their association via both
BRD and ET domains, BET proteins are known to be involved
in many cellular processes, including control of transcription,
regulation of DNA replication and cell cycle through “reading” of
cellular histone lysine acetylation marks and acting as a scaffold
for transcription factor recruitment. Due to their association
with transcriptional dysregulation in various lymphomas and
leukaemias, BET proteins, and more specifically BRD4, have
become important targets for cancer treatment and, as such,
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many small molecule inhibitors are now available (Bhattacharya
et al., 2018; Cochran et al., 2019). Interestingly, BRD4 inhibitors
either alone or in combination have been shown to cause
reactivation of HIV and have shown some promise in “shock
and kill” pre-clinical studies (Halper-Stromberg et al., 2014; Cary
et al., 2016; Nehme et al., 2019). Here, we briefly review the
known interactions between herpesvirus lifecycles and the host
BET proteins and also the effects that BRD inhibitors (BRDi) have
been found to have at the molecular level (Figure 1) and within
the clinical setting toward whether BRDi could be used routinely
for herpesvirus-related disease.
BET BROMODOMAIN INHIBITION AND
GAMMAHERPESVIRUSES
The initial specificity of BET BRDis allowed targeting of the
ability of BET proteins to bind to acetyled lysine marks on
histones found at active areas of the host genome, thereby
inhibiting the cellular transcriptional dysregulation occurring in
malignancies such as sarcoma and leukemia (Filippakopoulos
et al., 2010; Dawson et al., 2011). Due to the association of
gammaherpesviruses with various cancers, it is not surprising
that the majority of virus publications including the use of BET
BRDis involve infection with these herpesviruses in particular.
After primary infection, the two human gammaherpesviruses
Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated
herpesvirus (KSHV) can reside latently in B lymphocytes. While
both viruses are associated with various lymphomas, EBV is
also an etiologic agent of gastric cancers and nasopharyngeal
carcinomas (NPCs) (Farrell, 2019). EBV is unique in the human
herpesviruses by its use of distinct latency transcription profiles
in which a few select viral gene products including the latent
membrane proteins (LMPs) and EBV nuclear antigens (EBNAs),
driven from separate promoters on the virus genome, are
expressed in a B cell differentiation-specific manner. These
different latency transcription programs (Lat I-III) are known
to be regulated, at least in part, through epigenetic modification
to viral chromatin (Hammerschmidt, 2015). Application of the
most widespread BET BRDi inhibitor, JQ1 (Filippakopoulos
et al., 2010), to EBV-infected Burkitt lymphoma (BL) cell lines
caused a decrease in transcription from the C promoter (Cp) (a
necessary process in cellular immortalization) but, interestingly,
not the LMP1 promoter (Palermo et al., 2011). Inhibition of
BRD4 interaction through acetylated histones at Cp was shown to
decrease the recruitment of the positive transcription elongation
factor (P-TEFb) complex, composed of cyclin T1 (CycT1) and
cyclin-dependent kinase 9 (CDK9), the latter which activates
poised/paused RNA polymerase II (RNAPII) by phosphorylation
of serine 2 on the C-terminal domain (CTD) (Chen et al., 2018).
This JQ1-driven mechanism also inhibits the expression of host
genes in EBV-infected cell lines, whereby transcription from
virus-modulated host super-enhancers, such as that controlling
MYC expression, is restricted. Here, MYC down-regulation led
to growth inhibition of lymphoblastoid cell lines (LCLs) (Zhou
et al., 2015), which was also consistent with treatment of NPC
cell lines elsewhere (Li et al., 2018).
Most promising therapeutically is a report of BRDi allowing
depletion of LCLs in an ex vivo co-culture setting. JQ1 treatment
caused up-regulation of LMP1 and subsequent modulation of
down-stream signaling pathways as well as increased MHC class
I presentation, the latter likely allowing cytotoxic T cells to
target once hidden cells (Smith et al., 2016). Indeed, BRDi (JQ1
and iBET-762, a benzodiazepine-based BET BRDi) (Nicodeme
et al., 2010; Mirguet et al., 2013) treatment of a BL cell line
with EBV in latency I (Q promoter driven transcription) added
further evidence as to the possible safety of using these inhibitors;
BRDi caused inhibition of host BACH1 expression, which is
necessary to drive virus reactivation through the immediate early
(IE) protein BZLF1 (Keck et al., 2017). Concomitant inhibition
of BRD4 interaction with the EBV origin of lytic (oriLyt)
replication caused complete prevention of EBV lytic cycle and,
as such, would provide favorable conditions for treatment of
EBV-associated malignancies.
Analogous to EBV, KSHV gene expression and latency
is controlled by epigenetic modification (Chen et al., 2013)
and, as such, BRDi have been trialed in pre-clinical studies
of KSHV-associated malignancies. Either JQ1, iBET-151 or
PFI-1 (a dihydroquinazoline-2-one BET BRDi) (Picaud et al.,
2013) treatment of primary effusion lymphoma (PEL) cells
has shown decreased cell and tumor growth rates, as well
as increased survival, in PEL xenograft models (Tolani et al.,
2014; Gopalakrishnan et al., 2016; Zhou et al., 2017). However,
effects to PEL cell growth were predominantly caused by the
down-regulation of MYC expression. KSHV reactivation, and
subsequent oncolysis, was only initiated when cells were co-
treated with JQ1 and an NF-κB-activating compound (PEP005)
(Zhou et al., 2017). This is in contrast to reports elsewhere
of KSHV reactivation with BET BRDi alone (Chen et al.,
2017; Hopcraft et al., 2018), although the disparity in results
may be due to the range of PEL cell and reporter lines
used across all of these studies, some of which are also EBV-
positive. In a sophisticated study, the Lieberman laboratory
resolved the molecular mechanism of BET BRDi-induced KSHV
reactivation; using JQ1, they showed that the three-dimensional
(3D) looping conformation of the KSHV genome that maintains
the expression of latent transcripts (Chen et al., 2013) was
destabilized such that lytic expression ensued (Chen et al., 2017).
The presence of both BRD2 and BRD4 proteins on the virus
genome was demonstrated to stabilize transcription at the latency
control region producing the latency-associated nuclear antigen
(LANA), whilst interaction of BRD2/4 with LANA protein itself
was seen at virus genome terminal repeats (TRs) regulating loop
structure. With BET protein inhibition, LANA was released from
the KSHV genome causing the shift in 3D conformation and
virus reactivation (Chen et al., 2017).
As well as maintaining the latent expression profile of KSHV,
the LANA protein also acts as a viral episome maintenance
protein (EMP) tethering the extrachromosomal genomes to
host chromosomes through interaction with host proteins.
Human gammaherpesvirus EMPs appear to interact with at least
BRD4 (De Leo et al., 2020) and, as such, could be targeted
therapeutically with BET BRDi to restrict genome carriage. One
study with racoon polyomavirus (RacPyV), a small DNA virus
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FIGURE 1 | BET bromodomain inhibitor (BRDi) effects on human herpesvirus (HHV) infection. Diagram summarizes the published effects of BET BRDi treatment on
viral gene expression of both HHV latent (Left) and lytic (Right) infections. Briefly, BET BRDi treatment of cells causes release of BRD4 (thick gray arrow) from DNA,
repressing host transcription, reactivation of EBV and cell growth. Dissociation of BRD4 (and BRD2) from virus genomes can both inhibit DNA replication (EBV) and
reactivate KSHV, whilst release and redistribution of P-TEFb causes both reactivation and lytic augmentation of HSV. Effects of BET BRDi on HCMV are largely
unknown. Elements of figure not to scale. IE, immediate early; mRNA, messenger RNA; vDNA, viral DNA.
shown to tether its genome to the host chromosome with BRD4,
showed promising results with JQ1-induced reductions in viral
transcripts and genome copy number in neuroglial tumor cells
(Church et al., 2016). However, given that BRDi treatment
reactivates KSHV (Chen et al., 2017; Hopcraft et al., 2018) and
BRD4 depletion in an EBV-infected NPC cell line didn’t affect
genome segregation (Lin et al., 2008), thismight be a less tractable
therapeutic angle with HHVs.
BET BROMODOMAIN INHIBITION AND
ALPHAHERPESVIRUSES
The human alphaherpesviruses are characterized by latent
infection of cells of the nervous system from where they
are able to cause repeated pathology. Herpes simplex virus-
1 (HSV-1),−2, and VZV primarily infect cells of the mucosal
epithelia before dissemination to sensory neurons of the
peripheral nervous system (Arvin et al., 2007). VZV is named
directly after the clinical symptoms associated with infection,
varicella (chickenpox) and zoster (shingles), the latter being
associated with virus reactivation. Both are normally self-
limiting, with severe pathology usually only arising in the
immunocompromised host (Steiner et al., 2007). VZV is the only
herpesvirus for which an effective vaccine has been developed
and, as such, has been available for immunization of children in
the USA since 1995 (Field and Vere Hodge, 2013). No studies of
VZV and BET proteins or their inhibitors have been reported.
In contrast to VZV, investigation into the effects of BET
BRDi on HSV during lytic and latent infection has recently
been reported. Due to the cellular tropism of the simplex
viruses, reactivation events of HSV-1 and -2 can repeatedly cause
epithelial lesions both orally (cold sores) and genitally, with
occasional transfer to the central nervous system giving rise to
encephalitis and systemic disease (Whitley and Baines, 2018).
Like other herpesviruses, HSV gene expression during both
lytic and latent infection is governed by epigenetic regulation
(Kristie, 2015) and, thus, led to investigation of a number of
BET family inhibitors. Employment of JQ1, as well as other
BET BRDi (iBET-762, HMBA, and PFI-1), over two studies has
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shown increases in HSV transcript levels, protein production
and virus output from lytic infection systems (Ren et al.,
2016; Alfonso-Dunn et al., 2017). Indeed, JQ1 was also able to
reactivate HSV-1 from a mouse sensory ganglia explant and in
vivo mouse models (Alfonso-Dunn et al., 2017). Both studies
showed the enhanced association of CDK9, the transcriptional
activator of the P-TEFb complex, with HSV promoters driving
virus transcription. The Li group provided evidence that P-
TEFb was reallocated to virus promoters by BRD4 after JQ1
treatment, supported by experiments using small interfering
RNAs (siRNA) targeting BRD4 to decrease virus transcription
(Ren et al., 2016). However, the Kristie group showed association
of P-TEFb after JQ1 treatment to be independent of BRD4 at
the virus genome, with depletion of BRD4 with siRNA causing
increases in HSV IE transcript levels (Alfonso-Dunn et al., 2017).
The latter mechanism was determined to be caused by the
release of P-TEFb from repressive 7SK snRNP complexes in the
cytoplasm (Bartholomeeusen et al., 2012), comparable to HIV
studies elsewhere (Biglione et al., 2007), with recruitment being
through AFF4 and the super elongation complex (SEC) (Chen
et al., 2018). Interestingly, use of RVX-208 which targets BD2
of BRD4, showed no effect on HSV replication, confirming that
regardless of downstream mechanism, JQ1 interferes with BRD4
activity through interaction via BD1 (Ren et al., 2016).
Outside of human herpesviruses, a study on the swine
alphaherpesvirus pseudorabies virus (PRV) has identified various
means by which BRD4 inhibition can affect lytic virus infection.
Use of three different compounds (JQ1, OTX015, and iBET-151),
alongside confirmatory data with siRNA use, has recently shown
that inhibition of BRD4, due to its importance in maintenance
of higher-order chromatin structure (Wang et al., 2012), can
lead to activation of the DNA damage response by chromatin
de-compaction (Wang et al., 2020). In concert with induction
of interferon-stimulated genes (ISGs), including IFN-β, DNA
damage triggers activation of cGAS-mediated innate immunity
and is able to attenuate attachment of the virus to the surface
of BRDi-treated cells (Wang et al., 2020). In the absence of any
effects to virus transcription, this BRDi-driven induction of an
anti-viral state caused not only restriction of PRV infection in
cell lines but also in an in vivo mouse model (Wang et al.,
2020). Importantly, this sole study provides further evidence
that BET BRDi can have diverse effects on virus infections
via various means but also that they might be used as a
future therapy.
BET BROMODOMAIN INHIBITION AND
BETAHERPESVIRUSES
In contrast to alpha- and certainly gammaherpesviruses,
little work has been published with use of BRDi during
betaherpesvirus infection. In the absence of any investigation
with roseolaviruses, HHV-6 and -7, observations have been
made during lytic infection with the prototypic betaherpesvirsus,
HCMV. HCMV maintains latency within CD14+ monocytes
and CD34+ cells of the myeloid lineage, but only after primary
infection and dissemination, which is thought to occur through
productive infection of oral epithelial cells (Sinclair and Sissons,
2006). It is now clear that a number of viral genes are
expressed during HCMV latency (Sinclair and Reeves, 2013)
and maintenance of this phase takes place through epigenetic
regulation and chromatin modification of the virus major
immediate early promoter (MIEP) in order to repress the
expression of the IE1/IE2 genes (Sinclair, 2010). Reactivation of
the MIEP is usually associated with differentiation of cells to
macrophage or dendritic cells (DCs) and the resulting changes to
expression of host transcription factors. In turn, the production
of the immediate early proteins IE72/IE86 leads to initiation of
the usual cascade of herpesvirus gene expression, with early then
late gene expression following during a full productive lytic cycle.
It is known that within the first 8 h of permissive infection with
clinical isolates of HCMV, BRD4 along with CycT1 and CDK9
(the RNAPII-activating P-TEFb complex) accumulate at nuclear
sites, known as the transcriptosome, where the transcriptionally
active HCMV genome resides (Kapasi and Spector, 2008).
BRD4 is able to recruit P-TEFb through its interaction with
CycT1, however it has been reported that the presence of
CDK9 at these transcriptosomes can be inhibited with CDK9
activity inhibitors (Kapasi and Spector, 2008). Hence, the direct
relationship between these three proteins during HCMV is not
fully understood. Regardless, the possibility that BRD4 may
be recruiting the activating P-TEFb to the MIEP makes it an
attractive target for inhibition, at least during lytic infection.
In fact, work using the BRDi OTX015 (Noel et al., 2013) in
a screen for anti-viral compounds, shown elsewhere to cause
reactivation of HIV from latency (Lu et al., 2016), caused a
decrease in the level of productive infection using an HCMV
tegument protein pp28 GFP-tagged virus (Arend et al., 2017).
Although this decrease in late protein expression could have been
due to an initial restriction in transcription from the MIEP, the
authors speculated that the effect may be due to an interference
of the involvement of BRD2 in the replication of virus DNA, a
necessary precursor to late herpesvirus gene expression (Arend
et al., 2017).
The only other employment of BRDi during HCMV infection
has shown little effect on the lytic cycle of the virus, albeit
at only 2 h post-infection. The study by the Kristie group on
BRDi-induced reactivation of HSV-1 also assessed the effect of
JQ1, iBET-762 and HMBA on HCMV. However, in contrast
to effects on HSV-1, little to no change in the level of
immediate early (IE72) or early (UL44) transcripts was seen,
consistent with the effects of BRD4 depletion with siRNAs
(Alfonso-Dunn et al., 2017). Interestingly, though, reactivation
of HSV-1 was shown to be dependent on the release of P-
TEFb from repressive 7SK snRNP complexes in the cytoplasm
(Bartholomeeusen et al., 2012), comparable to HIV studies
elsewhere (Biglione et al., 2007), and the effect of BET BRDi
on HCMV latently infected cells remains untested. Likewise, the
possibility of BET BRDi employment for treatment of HCMV-
associated cancers, where the virus has been reported to have
an oncomodulatory role possibly through MYC dysregulation
as seen with gammaherpesviruses (Herbein, 2018; Cobbs, 2019),
has yet to be studied. However, given the varied effects of these
inhibitors on both herpesvirus latent and lytically infected cells,
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as well as other human pathogenic viruses, these applicationsmay
be worthy of investigation.
DISCUSSION
The life cycles of many HHVs are known to be dependent on the
activity of BET proteins at various stages throughout infection.
Depending on the virus, BRD4 is integral for the control of HHV
transcription (both latent and lytic), virus DNA replication and
is associated, at least in part, with viral genome maintenance.
Thus, small molecule inhibitors of BET proteins may make
effective treatments at certain points during infection. Although
BET BRDis cause HSV reactivation and augmentation of lytic
infection, treatment of cells productively infected with EBV
restricts viral lytic DNA replication, which may be common to
treatment of HCMV lytic infection. However, themost promising
effect of BET BRDi thus far has been its ability to control
KSHV-infected tumor growth in mouse xenograft models. Here,
restriction of host gene expression, such as MYC, limits cellular
proliferation. However, it is presentation of viral lytic antigens
after KSHV reactivation that allows infected cell targeting by
pre-existing cytotoxic T cells. This scenario is akin to known
“shock and kill” therapies for HIV patients where latency reversal
agents (LRAs) have been trialed to varying efficiency to reduce
latent HIV carriage (Thorlund et al., 2017; Ait-Ammar et al.,
2019). However, to date, no treatment has shown complete
removal of the latent HIV reservoir. While a curative treatment
for viruses such as HIV would be highly beneficial, purging the
latent reservoir of certain HHVs should prove advantageous to
individuals undergoing, for example, stem cell or solid organ
transplantation. Here, it has been proposed that the use of LRAs
in HCMV seropositive donors and recipients prior to harvest
and engraftment could allow purging of the latently infected cells
and, as such, reduce reactivation event-related disease during
immune suppression post-transplant (Poole et al., 2014; Wills
et al., 2015). A pre-clinical study from our laboratory has shown
the efficiency of using HDACi to induce HCMV lytic antigen
production as a target for T cells (Krishna et al., 2016). With this
in mind, we are now actively investigating the use of BET BRDi
on latency/reactivation of HCMV as the basis for a refined “shock
and kill” strategy to target the latent reservoir.
As a result of the success of BET BRDi use in the oncology
setting, newer generations of BET-specific molecules are being
designed. One approach is to target the protein of choice for
proteasome-dependent degradation using Proteolysis Targeting
Chimeras (PROTAC) (Cochran et al., 2019). Indeed, dBET1-
targetting of BET proteins (Winter et al., 2015) showed similar
increases of IE transcripts in HSV lytically infected cells when
compared to pan-BET BRDi, such as JQ1 (Alfonso-Dunn et al.,
2017). However, the effects of this style of molecule are not
yet known during latency of the HHVs. A further strategy
which may prove useful is the novel “block and lock” method,
whereby small molecules are used to inhibit transcription from
the viruses and lock promoters in a latent state (Nehme et al.,
2019). Amongst various targets, a BRD4 BD1-specific compound
(ZL0580) has recently shown the ability to “functionally cure”
HIV by inhibiting Tat transactivation of the HIV promoter
whilst causing chromatin-based repression (Niu et al., 2019;
Vansant et al., 2020). Although this strategy might not allow
targeting of infected cells to reduce latent carriage, the ability
to inhibit reactivation of HHVs during treatment such as
transplantation is alluring, whilst the possibility of inhibiting lytic
infection in other clinical scenarios is particularly exciting. Be
that as is may, further robust pre-clinical investigation will be
necessary to confirm the potential of BET protein inhibitors as
therapeutics for intervention of HHV-associated disease before
human application.
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